Autres langues Ildong Pharmaceutical Co., Ltd.

Actions

A249420

KR7249420001

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 10/05/2024			Varia. 5j.	Varia. 1 janv.
15 440 ^KRW	-1,40%		-0,77%	-14,98%

2023	Ildong Pharmaceutical Co. publie ses résultats pour le premier trimestre clos le 31 mars 2023	CI
2023	Ildong Pharmaceutical Co., Ltd. dépose une demande de nouveau médicament auprès de la MFDS pour l'indication de l'infection par le SRAS-CoV-2, et cette demande a été acceptée pour examen par la MFDS	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea	29/12
Il Dong Pharmaceutical Introduces New R&D Unit Yunovia	06/11
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 30 billion in funding	20/10/23
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 30 billion in funding	18/10/23
Ildong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Il Dong's Application for Shionogi's COVID Oral Medication Accepted for Review in South Korea	04/01/23
Ildong Pharmaceutical Co., Ltd. Files a New Drug Application with the MFDS for the Indication of SARS-CoV-2 Infection, and This Application Has Been Accepted for Review by MFDS	04/01/23
Shionogi JV Sub-licenses COVID-19 Drug to South Korea's Il Dong Pharmaceutical	19/09/22
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology	30/06/22
Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology	30/06/22
Ildong Pharmaceutical : Interim Report on Business Performance (Fair Disclosure)	17/02/22
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills	29/12/21
Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug	29/11/21
Ildong Pharmaceutical : starts Phase 1 study of new diabetes therapy in Germany	01/07/21
Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany	01/07/21
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in funding	28/01/21
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 100 billion in funding	18/01/21
MÄRKTE ASIEN/Impfstoff-Hoffnung und Biden-Amtsübergabe stützt	24/11/20
Evotec SE and Ildong to Collaborate with Development Projects on Indigo Platform	31/03/20
Ildong Pharmaceutical Co., Ltd. Enters into Co-Promotion Agreement with GSK Consumer Healthcare SA	05/12/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ildong Pharmaceutical Co., Ltd.

Actions

A249420

KR7249420001

Autres langues

Filtres